Clinical Trials Logo
  1. Home
  2. Fibrillation, Atrial
  3. NCT03401931
  4. Details
NCT03401931 Clinical Trial

Artificial Intelligence Use for the Detection of Atrial Fibrillation Drivers

Fibrillation, Atrial Clinical Trial

— AI Fib  

Official title:
Artificial Intelligence Use for the Detection of Atrial Fibrillation Drivers

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT03401931
Other study ID # HSJ_AIFIB_2017
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date January 9, 2018
Est. completion date January 9, 2018

Study information
Verified date April 2020
Source Hospital St. Joseph, Marseille, France
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

pilot clinical study, multicenter, prospective, open, nonrandomized

Description:

The hypothesis is that ablation targeting PVI alone for the treatment of persistent AF is less efficient that ablation targeting electrophysiologic areas with spatio-temporal-dispersion with or without PVI

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date January 9, 2018
Est. primary completion date January 9, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: major patient with an indication of AF or AT ablation -

Exclusion Criteria:

-

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
France Hopital d'Aix en Provence Aix-en-Provence
France CHU Nice Nice
Netherlands Isala Hospital Zwolle Netherland

Sponsors (1)
Lead Sponsor Collaborator
Hospital St. Joseph, Marseille, France

Countries where clinical trial is conducted

France,  Netherlands, 

Outcome
Type Measure Description Time frame Safety issue
Primary AF termination conversion to sinus rhythm or stable atrial tachycardia during the ablation procedure
Secondary AT termination conversion to sinus rhythm during the ablation procedure
See also
  Status Clinical Trial Phase
Completed NCT00244725 - Odiparcil For The Prevention Of Venous Thromboembolism Phase 2
Terminated NCT00437242 - Odiparcil QT Definitive Study Phase 1
Completed NCT00402363 - Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation Phase 3
Completed NCT00240643 - Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke Phase 2
Completed NCT00041496 - Prevention Of Recurrence Of Atrial Fibrillation Phase 2
Not yet recruiting NCT06200311 - Atrial Fibrillation (AF) Ablation to Prevent Disease Progression of AF-induced Atrial Cardiomyopathy in Women and Men N/A
Completed NCT04537507 - Atrial Fibrillation and Non-obstructive Coronary Lesions
Completed NCT04761315 - Detecting Atrial Fibrillation in Patients With an Embolic Stroke of Undetermined Source (From the DAF-ESUS Registry)
Completed NCT00911300 - Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm Phase 2